Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US45256X1037
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG007T9DYW9
IBRX
Immunitybio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Immunitybio Inc
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Di., 31.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       ImmunityBio
US45256X1037

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purc...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       ImmunityBio
US45256X1037

Boston, Massachusetts--(Newsfile Corp. - March 30, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its executives. Investors who have lost money in their ImmunityBio investment should contact the firm to learn more about how they might recover those losses....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON IM...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith announces an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALL...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       ImmunityBio
US45256X1037

The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during t...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       ImmunityBio
US45256X1037

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Sa., 28.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Sa., 28.03.2026       ImmunityBio
US45256X1037

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Cap...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investmen...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 1...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IMMUNITYBIO, INC. (IBRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This press...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

SAN DIEGO, March 27, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the Immuni...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       ImmunityBio
US45256X1037

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, emai...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       ImmunityBio
US45256X1037

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunityBio investors under the federal secur...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 26.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring Committee (IDMC) review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete respons...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       ImmunityBio
US45256X1037

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       ImmunityBio
US45256X1037

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses on ImmunityBio executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased ImmunityBio securiti...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA’s initial presence in Asia and reflects the Company’...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the t...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       ImmunityBio
US45256X1037

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       ImmunityBio
US45256X1037

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary diseaseThe FDA reviewed the additional data provided by ImmunityBio in February 2026, and based on the Agency's feedback, the Company resubmitted the sBLAThe FDA has acknowledged receip...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conferen...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       ImmunityBio
US45256X1037

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit c...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA, representing an approximately 700% increase year-over-year. The Company also reported a 750% increase in unit sales volume and a 20...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA re...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       ImmunityBio
US45256X1037

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcino...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       ImmunityBio
US45256X1037

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cance...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       ImmunityBio
US45256X1037

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       ImmunityBio
US45256X1037

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That pipelin...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       ImmunityBio
US45256X1037

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       ImmunityBio
US45256X1037

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That pipelin...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance h...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       ImmunityBio
US45256X1037

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. The outpatien...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       ImmunityBio
US45256X1037

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 23.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent o...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle inva...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 16.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026....
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Fr., 16.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity nat...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. ImmunityBio reported preliminary net product revenue of approximately $38.3 million during the three-month period ending December 31,...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink
Mi., 14.01.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ,...
Zur Nachricht
ImmunityBio
Charts & Research Termsheets Terminal
Permalink